Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. uri icon

Overview

abstract

  • Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.

publication date

  • February 1, 2017

Research

keywords

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Medical Oncology
  • Multiple Myeloma
  • Stem Cell Transplantation

Identity

Scopus Document Identifier

  • 85016214542

PubMed ID

  • 28188192

Additional Document Info

volume

  • 15

issue

  • 2